Aguilar Jorge, Averbukh Yelena
Montefiore Medical Center, Bronx, New York.
Perm J. 2020;24. doi: 10.7812/TPP/20.158.
The growing coronavirus disease 2019 (COVID-19) pandemic initially led to widespread use of hydroxychloroquine sulfate as an off-label experimental treatment of this disease.
Acute hemolytic anemia developed in an African American man with COVID-19-related pneumonia and glucose-6-phosphate dehydrogenase (G6PD) deficiency who completed the standard 5-day experimental course of hydroxychloroquine. Although the trigger leading to our patient's hemolytic sequelae will never be known with certainty, his clinical course suggests that hydroxychloroquine use and/or COVID-19 infection may trigger hemolysis in susceptible patients with G6PD deficiency.
This case confirms recent findings that the potential risks of hydroxychloroquine therapy for COVID-19 may outweigh the benefits.
2019年冠状病毒病（COVID-19）疫情的不断蔓延，最初导致硫酸羟氯喹被广泛用作这种疾病的非标签实验性治疗药物。
一名患有COVID-19相关肺炎且葡萄糖-6-磷酸脱氢酶（G6PD）缺乏的非裔美国男性，在完成了标准的5天羟氯喹实验疗程后，出现了急性溶血性贫血。虽然导致我们这位患者溶血后遗症的确切诱因永远无法确定，但他的临床病程表明，使用羟氯喹和/或感染COVID-19可能会在G6PD缺乏的易感患者中引发溶血。
该病例证实了近期的研究结果，即羟氯喹治疗COVID-19的潜在风险可能超过其益处。
